Axsome Therapeutics, Inc. has successfully completed its phase 3 clinical program for AXS-05 in treating Alzheimer’s disease agitation. The ACCORD-2 trial achieved the primary endpoint by ...
Shares of Southern have moved -1.0% today, and are now trading at a price of $82.28. In contrast, the S&P 500 index saw a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback